AGP Executive Report
Last update: 8 hours agoFDA Approvals: The FDA cleared adjuvant belzutifan (Welireg) plus pembrolizumab (Keytruda) for clear cell renal cell carcinoma after nephrectomy in intermediate/high recurrence-risk patients, backed by the LITESPARK-022 trial. Oncology Pipeline: AstraZeneca won FDA approval for capivasertib (Truqap) plus abiraterone and prednisone for PTEN-deficient metastatic hormone-sensitive prostate cancer, while Jazz’s Zepzelca (lurbinectedin) missed the main goal in a Phase III second-line small cell lung cancer study, putting its accelerated approval at risk. Medtech M&A: Deal momentum stayed strong in 2026, with major moves including Boston Scientific’s Penumbra bid and Abbott’s Exact Sciences tie-up, plus continued acquisitions and divestitures across the sector. Healthcare Access & Policy: CMS published final rules for accrediting organizations and HHS OIG flagged high denial rates for Medicare Advantage prior authorizations for long-term acute care and rehab. AI in Care: Research warns that “pushy” healthcare chatbots can reduce patient willingness to attend screening, and a separate report highlights friction when chatbots mimic humans without clear transparency. Public Health: The U.S. expanded Ebola countermeasure funding by $50M via CEPI, while India reported no new Nipah cases but kept quarantine and monitoring active.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.